Tegileridine Combined With Intercostal Nerve Block After Thoracoscopic Lung Resection

Recruiting now · Not applicable

Conditions studied: Lobectomy

In brief

Combining tegileridine PCIA with ICNB targeting peripheral nerves, may constitute an ideal analgesic model with complementary advantages. Thus potentially achieving the analgesic goal of "early pain relief, stable throughout the process, and rapid recovery," and may have a positive impact on reducing CPSP.

Key facts

Study ID

NCT07386626

Run by

Tongji Hospital

People needed

118

Starts

2026-03-18

Expected to finish

2027-01-31

Last updated by the study team

2026-04-08

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age range: 18 to 75 years old;
• Patients undergoing elective thoracoscopic lobectomy or segmentectomy;
• ASA classification levels I-III;
• BMI 18 \~ 30 kg/m2。
• Voluntarily participate and sign an informed consent form.

You may not qualify if…

• Patients with preoperative alcohol dependence and long-term use of analgesic drugs are receiving analgesic treatment for other acute and chronic pain;
• Pregnant or lactating women;
• Allergies or other contraindications to the anesthetics, analgesics, and antiemetic drugs used in the study;
• Patients with severe sleep apnea syndrome or acute or severe bronchial asthma;
• Suffering from mental and neurological disorders or cognitive impairment, known or suspected gastrointestinal obstruction, severe liver and kidney dysfunction (Child Pugh score C), chronic obstructive pulmonary disease or severe cardiovascular disease, etc;
• Researchers consider participants who are not suitable to participate in this study and those who refuse to participate.

Where it is running

• Tongji hospital — Wuhan, Hubei, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.